Brief: Palvella Therapeutics Strengthens Leadership With Appointment Of Accomplished Scientist And Biopharmaceutical Executive David W. Osborne, Ph.D. As Chief Innovation Officer
03/09/2025 13:31
Sept 3 (Reuters) - Arcutis Biotherapeutics Inc ARQT.O: PALVELLA THERAPEUTICS STRENGTHENS LEADERSHIP WITH APPOINTMENT OF ACCOMPLISHED SCIENTIST AND BIOPHARMACEUTICAL EXECUTIVE DAVID W. OSBORNE, PH.D. AS CHIEF INNOVATION OFFICER Source text: ID:nGNX7zqn0P Further company coverage: ARQT.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Arcutis Biotherapeutics
See all newsBrief: Arcutis Biotherapeutics reports inducement grants under Nasdaq listing rule 5635(C)(4
Arcutis Q1 product revenue rises 65% yr/yr, net loss narrows
Brief: Arcutis Announces Promotion Of MAS Matsuda To Executive Vice President And Chief Legal Officer To Support Next Phase Of Growth
Brief: Arcutis Begins Enrolling Phase 1A/1B Study Evaluating Arq-234, A Cd200r Agonist, In Healthy Volunteers And Adults With Atopic Dermatitis
Brief: Arcutis Biotherapeutics Inc Files For Mixed Shelf